Mount Sinai Health System, a National Cancer Institute‑designated Comprehensive Cancer Center in New York City, has entered into a partnership with SOPHiA GENETICS to implement the company’s SOPHiA DDM platform for next‑generation sequencing of blood‑cancer and solid‑tumor samples. The collaboration will enable Mount Sinai’s Molecular Pathology team to analyze complex genomic variants more efficiently, reducing manual interpretation time and improving turnaround for oncology patients.
SOPHiA GENETICS, which serves more than 990 global institutions, reported fourth‑quarter 2025 revenue of $21.7 million and full‑year 2025 revenue of $77.3 million, a 19% year‑over‑year increase. The company’s adjusted gross margin rose to 74.2%, up 140 basis points from the prior year, driven by scale‑related cost efficiencies and a higher mix of high‑margin AI‑driven contracts. Management reaffirmed 2026 revenue guidance of $92 million to $94 million, reflecting confidence in continued adoption of its federated AI platform.
CEO Jurgi Camblong said, "We finished 2025 strong, with Q4 revenue growing 22% and full‑year revenue increasing 19% year‑over‑year, as our growth momentum continues to accelerate." President Ross Muken added, "Our platform is purpose‑built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI."
The partnership expands SOPHiA’s presence in the United States, adding one of the country’s largest academic health systems to its network. By integrating the platform into its laboratory workflow, Mount Sinai will leverage SOPHiA’s federated AI architecture to process genomic data while preserving patient privacy, a key differentiator for the company’s cloud‑native solution. The deal is expected to generate additional platform usage revenue and strengthen SOPHiA’s competitive moat in the precision‑medicine data market.
The collaboration signals a broader strategic push by SOPHiA to scale its DDM platform across diverse clinical settings. With Mount Sinai’s support for over 4,000 oncology patients annually, the partnership positions SOPHiA to capture a significant share of the U.S. precision‑oncology market, reinforcing its growth trajectory and reinforcing its ability to monetize AI‑driven genomic analytics at scale.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.